$695 | Single User
$1395 | Global License

Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Dec 2013 | 87 | In Stock

Introduction

Scope



Already positioned as one of the most commercially promising new drug approvals of 2013, Algeta and Bayer's prostate cancer treatment Xofigo is now driving what appears to be the inevitable acquisition of the former by the latter.


Buoyed by a stronger than expected launch in Q3, a number of analysts have speculated that Bayer perceives there to be an increasingly more compelling outlook for Xofigo. One sufficient to drive the diligent German player to move for Algeta, despite the Norwegian company's value already reflecting strong anticipated uptake for the radiopharmaceutical - see In Focus: Bayer's M&A catalyst – FirstWord speaks to Xofigo's lead investigator.


Impressive Q3 sales, and confirmation that Bayer and Algeta are racing towards their target for initialising the specialist treatment centres that are required to prescribe the drug, have helped to diminish fears that Xofigo would face teething troubles due to its status as a radiopharmaceutical.


Longer-term prospects for Xofigo will be shaped by a number of factors, however, not least whether urologists and oncologists prescribe it in combination with other prostate cancer treatments such as Johnson & Johnson's Zytiga and Medivation and Astellas' Xtandi.


Its use in both the pre- and post-chemotherapy settings will also play a pivotal role in driving sales (its broad label permits such use), as will the potential to retreat patients after their initial run of six infusions.


Bayer recently confirmed that Phase III studies in combination with Zytiga have been initiated, but will read out in 2017. Some analysts appear concerned at both the study design – which does not have overall survival as its primary endpoint – and its relevance by 2017 (when existing therapies may have shifted to an even earlier position in the treatment paradigm).


Thus the mid-term performance of Xofigo could depend on whether physicians utilise a flexible approach towards the product, rather than wait for additional clinical data. As a completely separate mode of action, for example, there should be little mechanistic reason for not prescribing Bayer's drug in combination with Zytiga or Xtandi, note key opinion leaders (KOLs) interviewed by FirstWord's Therapy Trends team, although payers of course may need more convincing.


Puchase Reasons


To gain a better understanding of the outlook for Xofigo, this week's Physician Views poll will ask US-based urologists and oncologists...


  • Where in the prostate cancer treatment algorithm they are using/initially expect to use Xofigo?

  • Whether they will prescribe in combination with Zytiga/Xtandi prior to Phase III data?

  • How they assess the design of Bayer's Phase III combination study with Zytiga – and how results may/may not influence prescribing habits?

  • How logistically convenient the Xofigo treatment process has been since launch?

  • How comfortable they are with the concept of retreating patients after six initial courses of therapy?
  • Table of Contents
    for Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    87 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • 360i Research
    • 99Strategy
    • Allied Market Research
    • Asia Market Information & Development Co.
    • Azoth Analytics
    • BioInformant
    • Bizwit Research and Consulting
    • Black Swan Analysis
    • Canadean
    • CBR Pharma Insights
    • CRI
    • Current Analysis
    • Current Partnering
    • Daedal Research
    • Data bridge
    • Delve Insight
    • DPI Research
    • FirstWord Pharma
    • Future Market Insights
    • GBI Research
    • Global Data
    • Global Markets Direct
    • Global Research and Data Services GRDS
    • GMR Data
    • HeyReport
    • HongChun
    • HTStec
    • ICD Research
    • iGATE Research
    • IMARC
    • Industry ARC
    • Inkwood Research
    • IQ4I
    • Jain PharmaBiotech
    • Kelly Scientific
    • La Merie
    • Lifescience Intellipedia
    • LP Information
    • Market Data Forecast
    • Market Research Future
    • Marketline
    • MarketsandMarkets
    • McDerson
    • MedMarket Diligence
    • Meticulous Research
    • MicroMarketMonitor
    • MIReports
    • Mordor Intelligence LLC
    • MP Advisors
    • Occams Business Research
    • Prof Research
    • Progressive Markets
    • ProGrow Pharma Partners
    • Renub
    • Research Impact
    • RNCOS
    • Rockville Research
    • S&P Consulting
    • StratisticsMRC
    • The Business Research Company
    • Triton Market Research
    • Venture Planning Group (VPG)
    • VPA Research